Your email has been successfully added to our mailing list.

×
0.00102669404517452 0 -0.00102669404517452 0.00308008213552373 0 0.0071868583162218 0.00513347022587276 0.00513347022587276
Stock impact report

Ardelyx down as H.C. Wainwright downgrades rating on anticipated Xphozah sales drop [Seeking Alpha]

Ardelyx, Inc. (ARDX) 
Last ardelyx, inc. earnings: 3/6 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ardelyx.com/investor-relations
Company Research Source: Seeking Alpha
Wainwright downgraded the rating for the biopharmaceutical firm, saying that it anticipates a substantial drop in the company's kidney disease drug Xphozah sales in 1Q25 and beyond. Shares of Ardelyx were trading at $4.79 in the afternoon on Recommended For You More Trending News Show less Read more
Impact Snapshot
Event Time:
ARDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ARDX alerts
Opt-in for
ARDX alerts

from News Quantified
Opt-in for
ARDX alerts

from News Quantified